BfArM

The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is an independent federal higher authority within the German Federal Ministry of Health. Founded in 1995, BfArM is crucial for ensuring the safety and efficacy of drugs and medical devices in Germany and the EU. Its mandate includes assessing, authorizing, and supervising pharmaceuticals and medical products, thereby enhancing public health and patient safety through stringent regulatory standards.

BfArM operates with a significant workforce of 1,000 to 5,000 employees across two locations, supporting its extensive regulatory functions. The institute generates $228.5M in revenue, reflecting its substantial operational capacity and financial scale for comprehensive oversight and research. This scale facilitates robust engagement in complex scientific evaluations and administrative processes. Meet BfArM's team to learn about the expertise driving these critical public health initiatives.

The organization's activities are informed by hashtags indicating strong engagement in B2B, EU markets, IT, engineering, medical and health sectors, sales, marketing, and legal operations. BfArM's focus on B2B and EU markets underscores its international relevance and collaborative efforts. Its official web presence at www.bfarm.de provides essential information on regulatory functions, product approvals, and public health advisories, positioning BfArM as a vital component of Germany's healthcare infrastructure.